ASTRAZENECA PHARMA INDIA
|
|
BOM : 506820     NSE : ASTRAZEN     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Mar 22,2023 |
Price(EOD): ₹ 3,287.55
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 8,218.88 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
ASTRAZENECA PHARMA INDIA | 0.7% | -2% | 28% |
SUN PHARMACEUTICAL INDUSTRIES | 0.5% | -1.3% | 4.6% |
DIVIS LABORATORIES | -0.4% | -3.9% | -37.8% |
CIPLA | -2.3% | -10.4% | -17.8% |
DR REDDYS LABORATORIES | 2.1% | 0.1% | 10.3% |
TORRENT PHARMACEUTICALS | -2.2% | 2.5% | 9.6% |
ABBOTT INDIA | 3.6% | 7.2% | 23.2% |
ZYDUS LIFESCIENCES | -0.3% | 3% | 30.4% |
ALKEM LABORATORIES | 2% | -1.8% | -11.2% |
FUNDAMENTAL ANALYSIS OF ASTRAZENECA PHARMA INDIA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ASTRAZENECA PHARMA INDIA
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
74.71
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 110.01 Cr
[Latest Qtr - Dec2022 - Standalone Results ] 16.13
P/B Calculated based on Book Value of Rs 509.44 Cr
[Latest Year - Mar2022 - Standalone Results ] 8.65
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2022 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
64% 31% 33% |
SHARE PRICE MOMENTUM OF ASTRAZENECA PHARMA INDIA
ASTRAZENECA PHARMA INDIA vs SENSEX
DEBT OF ASTRAZENECA PHARMA INDIA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0 0 0 - |
- - - - |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF ASTRAZENECA PHARMA INDIA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF ASTRAZENECA PHARMA INDIA
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
5.79% -10.16% -10.47% -10.02% |
24.58% 149.47% 142.58% 156.6% |
QtrlyTrend |
2 | |
Latest Qtr: Dec2022 | ||
Quarterly Result Analysis → |
ASTRAZENECA PHARMA INDIA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 500 | 1% | -3.6% | -1.7% |
S&P BSE ALLCAP | 0.9% | -3.6% | -1.7% |
S&P BSE HEALTHCARE | 0.5% | -2.8% | -10.9% |
S&P BSE 250 SMALLCAP | 0.2% | -2.6% | -0.9% |
S&P BSE SMALL CAP | 0% | -3.1% | -1.9% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 | 1% | -3.6% | -1.8% |
NIFTY500 MULTICAP 50:25:25 | 0.7% | -3.3% | -1.4% |
NIFTY MID SMALL400 | 0.2% | -2.6% | 1.5% |
NIFTY SMALLCAP250 | 0.1% | -3.2% | -4.4% |
You may also like the below Video Courses
FAQ about ASTRAZENECA PHARMA INDIA
Is ASTRAZENECA PHARMA INDIA good for long term investment?
As on Mar 22,2023, the Fundamentals of ASTRAZENECA PHARMA INDIA look Strong and hence it may be good for long term investment! See Financial Performance of ASTRAZENECA PHARMA INDIA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ASTRAZENECA PHARMA INDIA UnderValued or OverValued?
As on Mar 22,2023, ASTRAZENECA PHARMA INDIA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of ASTRAZENECA PHARMA INDIA ?
As on Mar 22,2023, the Intrinsic Value of ASTRAZENECA PHARMA INDIA is Rs. 2,476.94 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 2,007.72
Fair Value [Median EV / Sales Model] : Rs. 2,515.28
Fair Value [Median Price / Sales Model] : Rs. 2,476.94
Estimated Median Fair Value of ASTRAZENECA PHARMA INDIA : Rs. 2,476.94
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is ASTRAZENECA PHARMA INDIA trading at a Premium or Discount?
As on Mar 22,2023, ASTRAZENECA PHARMA INDIA is trading at a Premium of 33% based on the estimates of Median Intrinsic Value!